CARIS LIFE SCIENCES, INC. Research and Development Expense
CARIS LIFE SCIENCES, INC. (CAI) reported Research and Development Expense of $32.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- CARIS LIFE SCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $32.36M, a 29.19% increase year-over-year.
- CARIS LIFE SCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $31.32M, a 35.76% increase year-over-year.
- CARIS LIFE SCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $31.84M, a 17.47% increase year-over-year.
- CARIS LIFE SCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $21.62M, a 21.78% decline year-over-year.
- CARIS LIFE SCIENCES, INC. research and development expense for fiscal 2025 was $101.58M, a 10.83% decline from fiscal 2024.
- CARIS LIFE SCIENCES, INC. research and development expense for fiscal 2024 was $113.92M, a 2.54% decline from fiscal 2023.
- CARIS LIFE SCIENCES, INC. research and development expense for fiscal 2023 was $116.88M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.36M 10-Q · filed 2026-08-05 | $63.67M 10-Q · filed 2026-08-05 | $95.52M derived: sum of 3 quarters · filed 2026-08-05 | $117.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $31.32M 10-Q · filed 2026-05-08 | $63.16M derived: sum of 2 quarters · filed 2026-05-08 | $84.78M derived: sum of 3 quarters · filed 2026-05-08 | $109.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $31.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $53.47M derived: sum of 2 quarters · filed 2026-03-03 | $78.52M derived: sum of 3 quarters · filed 2026-08-05 | $101.58M 10-K · filed 2026-03-03 |
| 2025-09-30 | $21.62M 10-Q · filed 2025-11-05 | $46.67M derived: sum of 2 quarters · filed 2026-08-05 | $69.74M 10-Q · filed 2025-11-05 | $96.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $25.05M 10-Q · filed 2026-08-05 | $48.11M 10-Q · filed 2026-08-05 | $75.22M derived: sum of 3 quarters · filed 2026-08-05 | $102.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $23.07M 10-Q · filed 2026-05-08 | $50.17M derived: sum of 2 quarters · filed 2026-05-08 | $77.82M derived: sum of 3 quarters · filed 2026-05-08 | $102.61M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $27.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $54.75M derived: sum of 2 quarters · filed 2026-03-03 | $79.54M derived: sum of 3 quarters · filed 2026-03-03 | $113.92M 10-K · filed 2026-03-03 |
| 2024-09-30 | $27.64M 10-Q · filed 2025-11-05 | $52.43M derived: sum of 2 quarters · filed 2025-11-05 | $86.81M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $24.79M 10-Q · filed 2025-08-12 | $59.16M 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | $116.88M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |